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To discuss outcomes with patients in daily clinicalpractice and to facilitate outcome comparisonsbetween institutions, a standardized outcome set forpatients with multiple myeloma (MM) is needed. The
goal of this study was to align outcome measurement in MM by
defining a set of outcomes most relevant for patients with MM
and defining instruments to measure these outcomes. The
outcome set was developed in 4 hospitals in the Netherlands.
To ensure feasibility, panelists with expertise or experience in
MM management across clinical specialties, patients and
scientific researchers, participated in in-depth group meetings.
Various information sources were used to identify a compre-
hensive list of outcomes. The list of potential outcomes was
refined through consensus discussions by focusing on outcomes
that had direct impact on patients, reflected clinical care, and
were feasible to measure in daily clinical practice. The defined
MM outcome set includes both clinical (eg, overall survival,
complications) as well as patient-reported outcomes (eg,
neuropathy, fatigue). Additional sociodemographic, clinical
and treatment characteristics were defined to allow for case-mix
risk-adjusted analyses. Recommended time-points for data
collection were determined. This study resulted in a standard
set of outcomes and accompanying instruments for use in daily
clinical practice for management and evaluation of MM patient
care. Implementation has started in five hospitals in the
Netherlands and will be evaluated. Future goal is to enroll an
outcome set in all hospitals in the Netherlands and abroad, in
order to carry out continuous and measurable improvement of
outcomes for patients with MM.
MM is a cancer of plasma cells and accounts for 13% of the
hematological malignancies.1,2 Because of widespread adoption
of new anti-cancer therapies, the survival of MM has increased
considerably in the last decades.3–5 In the Netherlands, the five-
year relative survival increased from 32% in the period 1996 to
2000 to 54% in 2011 to 2015, resulting in a 20-year prevalence
of 7100 patients in January 2018.1 Similar increases in survival
and prevalence have been reported worldwide.2 Many new
drugs, including monoclonal antibodies, next-generation pro-
teasome inhibitors and a next-generation immunomodulatory
agent were introduced in the past few years,3 providing more
options but adding complexity to the treatment of the disease.
Treatment strategies include longer treatment duration and
increasing number of treatment lines, accompanied by a higher
risk of side effects such as polyneuropathy, acute renal failure,
cardiac toxicity and pneumonia/infections. In addition, as many
patients with MM live longer, patients are also at risk for long-
term consequences of MM and/or MM treatment. Symptoms
such as fatigue, pain, neuropathy, cognitive problems and
depressive feelings are reported6–11 and are experienced more
frequently by patients with MM as compared to people without
cancer of the same age and sex.12 These symptoms have shown
to negatively impact patients’ health-related quality of life
(HRQoL).12–17
With the continuing changes in treatment, related (long-term)
side effects and the complexity and costs of treatment of
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patients with MM, the goals of treatment and therapeutic
decision making need to be expanded besides improvement in
overall survival to include several previously overlooked items
such as HRQoL, managing (long-term) side effects and refining
duration of therapy. Although there are efforts to measure
clinical outcomes (eg, survival, response status) a standard
approach is lacking,18 resulting in significant variation in
methods of measuring and reporting outcomes. In addition,
patient-reported outcomes (PROs) are very infrequently
assessed in daily clinical practice. PROs however, can be more
meaningful to patients compared to clinical outcomes18 and
can contribute to improving shared decision making and
management of patients with MM19.
Since an agreed standard approach is missing, the ability to
discuss outcomes with individual patients and to perform
comparisons of outcomes between institutions that could lead
to improvement of care is limited. Defining standardized and
patient-centered outcome measurement sets are therefore essen-
tial to improve care. The International Consortium for Health
Outcomes Measurement (ICHOM) focuses on developing such
standard sets for various diseases,20 whereby according to the
framework of value-based healthcare (VBHC) the key is
measuring outcomes that matter most to patients21 in addition
to clinical outcomes.
The goal of this study was to develop a standard set of
outcomes in MM by 1) defining a set of outcomes that are
most relevant to patients with MM, and 2) defining instru-
ments to measure these outcomes for use in daily clinical
practice. This standard set of outcomes will enable discussion
with individual patients and compare outcome between
institutions and health-care professionals with the ultimate
goal to improve MM patient care within the Netherlands
and abroad.
Working team and process
The development of an outcome set was undertaken by four
hospitals in the Netherlands. Panelist consisted of patients (N=4
of which 3with partner) and experts in the field ofMM, including
hematologists (N=4), nurse practitioners specialized in hema-
tology (N=6), a social worker (N=1), a physical therapist (N=
1), hospital care organizers (N=3), scientific researchers from the
Netherlands Cancer Registry (N=3) participated in in-depth
group meetings. The participating patients varied in age, sex,
phase in their care cycle, clinical experience and came from
different geographical regions of the Netherlands. The detailed
work process is provided in supplement (Supplement 1, http://
links.lww.com/HS/A82).
Defined population
Panelists agreed that a set of standardized outcome measures
should be defined for patients with ‘symptomatic Multiple
Myeloma’ ≥18 years of age who fulfill the International
Myeloma Working Group (IMWG) criteria.22 The precise
definition of the medical condition that was defined is
displayed in Figure 1. Exclusion criteria that were defined
are: patients aged <18, patients with treatment contra-
indication and patients with MGUS (Monoclonal gammopathy
of undetermined significance) or with Smouldering (asymp-
tomatic) MM. Furthermore, the starting and end point of care
were defined and a care pathway most ideal for MM patients
was described.
The standard set: outcome domains and
measures
Many potential outcomes were considered by the panelists
before agreement on the standard set of outcomes recommended
for patients with MM. It was decided that the clinical outcome
“time to relapse”whichwas selected in step 1Awas excluded from
thepreliminaryoutcome set, to keep the set as compact and feasible
to measure as possible. Quality of death, relationship/marital
problems, sexual problems and fear of physical exercise were
selected in step 1B, but not in 1A.Theywere included in thefinal set
as they were indicated to be very important to patients. The
standard outcome set includes both clinical outcomes and PROs.
Clinical outcomes
1. Survival: MM is a disease of the elderly with a relative short
life expectancy. Therefore, overall survival (OS, defined as the
length of time from diagnosis until death) captures the ultimate
impact of care and was included in the outcome set. In
addition, the working team decided to also include the three-
year progression free survival (PFS, defined as the length of
time from diagnosis and start of first line or subsequent
treatment until disease progression; Table 1).
2. Control of disease: Disease remission is one of the major goals
of MM treatment. Especially the period without needing
treatment was indicated as important by patients. Therefore,
therapy free interval was included in the outcome set, with the
definition listed in Table 1.
3. Adverse events: Side effects of treatment were listed as
important outcomes as they impact patients’ survival as well as
HRQoL. Although patients with MM are always treated
prophylactically with antiviral/bacterial therapy, many of
them still present themselves with infections.23 Also, motoric
and sensory neuropathy are frequently reported by patients as
a consequence of chemotherapy.11,16 For that reason,
infections and neuropathy were included in the outcome set
and scored according to the Common Terminology Criteria
for Adverse Events (CTCAE, version 5). In addition, kidney
failure, anemia, and venous thromboembolism were selected
for inclusion in the outcome set (Table 1).
4. Quality of death: Quality of death was indicated by patients as
an important outcome and will be evaluated with place of
death and active treatment <30 days prior to death.
Patient-reported outcomes (PROs)
Fatigue, (bone) pain, neuropathy, quality of life, dyspnea, and
being able to work were the most frequently mentioned
symptoms or subjects by patients participating in the discussion
groups. These themes were, amongst others, also found in the
literature that focused on PROs among patients with MM, both
internationally and in the Netherlands.6–17 HRQoL and
symptoms can most appropriately be captured by patients using
self-reported patient-reported outcome measures (PROMs).
PROMs used for patients with MM are the generic European
Organization for Research and Treatment of Cancer Quality of
Life Group Core questionnaire (EORTC QLQ-C30)24 and the
disease-specific EORTC QLQ Multiple Myeloma questionnaire
(EORTC QLQ-MY20).25 The EORTC QLQ-C30 includes five
scales on physical, role, emotional, cognitive, and social
functioning; a global health status/quality of life scale; three
symptom scales on fatigue, nausea and vomiting, and pain; and 6
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single items assessing dyspnea, sleeping problems, appetite loss,
constipation, diarrhea, and financial problems. The EORTC
QLQ-MY20 contains items on pain (bone, back, hip, shoulder,
chest) increase during activity, other disease symptoms and side
effects of treatment (e.g. tingling hands/feet, heartburn, burning/
sore eyes), one functional scale on future perspective, and one
single item on body image. Answer categories for the EORTC
QLQ-C30 and the EORTCQLQ-MY20 range from 1 (not at all)
to 4 (very much).24,25
These 2 questionnaires cover almost all symptoms that were
highlighted by patients and are translated and validated in
many languages and have been and are widely used
internationally.26 It was therefore decided to use these
questionnaires. However, some outcomes that were indicated
to be important were not covered by these questionnaires. For
the following topics a single item was selected: relationship/
marital problems, sexual problems and fear of physical
exercise. One item on neuropathy about tingling hands and
feet is part of the MY-20 questionnaire, however as this
problem is sometimes not experienced as tingling but as a numb
feeling an item about numbness was added. All except one (fear
of physical exercise) of these items were available in the
EORTC QLG Item Library27 and the wording and response
scale are therefore similar as the questions of the EORTC QLQ-
C30 and MY-20. All PROs that were included in the standard
set are listed in Table 1.
Timing and measurement process
The timing of measurement was determined based on clinical
relevance and feasibility. All clinical- and patient-reported
outcomes will be collected at time of diagnosis and 3, 9, 15,
and 21months after treatment, and subsequently annually. To be
able to discuss outcomes during visits, it is necessary to collect
PRO-data aligned with individual clinical care.
Case-mix factors
Several patient characteristics and risk factors are known to
influence patients’ outcomes. In order to make meaningful
comparisons, we therefore defined key patient characteristics to
be included in the set, that is, socio-demographic characteristics:
age, sex, education level/socio-economic status, health status;
clinical factors: cytogenetic risk, date of diagnosis, IMWG frailty
Patients ≥18 years old with symptomatic multiple 
myeloma with clonal bone marrow plasma cells or 
histologically proven plasmacytoma with:
•Organ or bone marrow dysfunction (CRAB-criteria):
-Hypercalcemia: Serum calcium >2.75 mmol/L
-Renal insufficiency: Serum creatinine ≥177 μmol/L
-Anemia: hemoglobin level decrease of ≥1.5 mmol/L or 
absolute value <6.3 mmol/L
-Bone lesions
-Other symptoms/signs (hyper viscosity, amyloidosis, 
bacterial infections). 
and/or
•Clonal plasma cells percentage ≥60%
•Free light chain ratio ≥100
•>1 unequivocal focal lesion on MRI 
Patient characteristics within medical condition
- More male than female
- Mean age ± 70 years
- A third aged >75
- 5% aged <45
Exclusion criteria
- Patients aged <18 
- Treatment contra-
indication
- MGUS
- Smoldering 
(asymptomatic) multiple 
myeloma
Starting point of care
1. Referral from Primary Care Physician, 
Medical Specialist (physician) or University 
hospital UMC because of suspected:
•Hypercalcemia
•Renal insufficiency
•Osteoporosis (fracture screening)
•Anemia
2. Clinical/biochemical Relapse
3. Refractory Multiple Myeloma
End point of care
1. Clinical/Biochemical Relapse
2. Refractory Multiple Myeloma
3. Death
Not included care Medical condition – included care Not included care
Figure 1. Definition of medical condition for which a set of standardized outcome measures is defined.
(2020) 4:3 www.hemaspherejournal.com
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score, comorbidity, (Revised) International Staging System
(R-ISS/ISS) stage,28 height, weight; treatment factors: type of
therapy, type of chemotherapy, therapy start and stop date and
treatment line. These selected factors are viewed to have a strong
and independent effect on the outcomes included in the set. All
case-mix factors and definitions are presented in Table 2.
This study resulted in a set of outcomes and accompanying
definitions or measures for patients with MM for use in routine
clinical practice. The outcomes represent important indicators
that are most relevant to patients. Additional sociodemographic,
clinical and treatment characteristics were defined to allow for
case-mix risk-adjusted analyses. With measuring the outcomes of
this set, we expect to be able to focus on meaningful results for
patients and health-care professionals, improve communication
between health-care professionals and patients, help to make
informed decisions about treatment options, assess performance
and guide improvements in clinical practice, and allow for
benchmarking.
Recently, an outcome set for patients with MM was defined in
Spain.29 At time of their publication, our development of an
outcome set had already started.When comparing the Spanish and
Dutch outcome sets, we observed a clear overlap. With respect to
the clinical outcomes, OS and PFS were included in both sets. In
Spain, minimal residual disease (MRD) and treatment response
werealso included in thisdomain.MRDwasnot included inour set
as it is not yet a routine test in theNetherlands. Treatment response
was not included to limit the number of outcomes. In addition,
complications and PROs were defined as outcomes in both sets,
Table 1
Outcome Domains and Definitions Included in the Standard Set.
Outcome Outcome definition/measure Timing Data source
Clinical outcomes
1. Survival
Overall survival (OS) The length of time from diagnosis until death Real time EMR Clinical data
3-year progression free survival (PFS) The length of time from diagnosis and start
of first line or subsequent treatment until
disease progression, calculated over a
period of three years
Real time EMR Clinical data
2. Control of disease
Therapy-free interval The period that patients do not receive active
treatment (i.e. chemo/immune therapy,
radiotherapy, stem cell transplantation)
Real time EMR Clinical data
3. Adverse events
Infections if CTCAE grade>=2; grade number Real time EMR Clinical data
Neuropathy CTCAE grade Real time EMR Clinical data
Kidney function failure If EGFR <30; yes, no, unknown Real time EMR Clinical data
Anemia Yes, no, unknown Real time EMR Clinical data
Venous thromboembolism Yes, no, unknown Real time EMR Clinical data
Secondary primary malignancy Yes, no, unknown Real time EMR Clinical data
4. Quality of death Real time EMR Clinical data
Place of death hospital? Yes, no, unknown Real time EMR Clinical data
Active treatment <30 days prior to
death
Yes, no, unknown Real time EMR Clinical data
Patient-reported outcomes
5. HRQoL (including impact on daily
activities, mobility, concentration, sleep,
nausea, lack of appetite, anxiety and
depressive symptoms, social participation,
work and financial impact)
EORTC QLQ-C30 At diagnosis, 3, 9, 15, 21 months after
treatment, then annually
Patient-reported data
6. Pain EORTC QLQ-C30 and EORTC QLQ MY-20 At diagnosis, 3, 9, 15, 21 months after
treatment, then annually
Patient-reported data
7. Neuropathy EORTC QLQ MY-20 on tingling hand and feet
and single item EORTC Item Library: Have
you experienced a numb feeling in your
hands or feet?
At diagnosis, 3, 9, 15, 21 months after
treatment, then annually
Patient-reported data
8. Fatigue EORTC QLQ-C30 and QLQ MY-20 At diagnosis, 3, 9, 15, 21 months after
treatment, then annually
Patient-reported data
9. Other symptoms (including back
problems, skin problems, gastric problems,
worries and fears, body-image)
EORTC QLQ MY-20 At diagnosis, 3, 9, 15, 21 months after
treatment, then annually
Patient-reported data
10. Relationship/Marital problems Single item from EORTC Item Library: Can
you talk about your illness with your
partner or the person closest to you?
At diagnosis, 3, 9, 15, 21 months after
treatment, then annually
Patient-reported data
11. Sexual problems Single item from EORTC Item Library: Are you
satisfied with your sex life?
At diagnosis, 3, 9, 15, 21 months after
treatment, then annually
Patient-reported data
12. Fear of physical exercise Single item: Are there physical activities that
you dare not to do due to your illness?
At diagnosis, 3, 9, 15, 21 months after
treatment, then annually
Patient-reported data
CTCAE= common terminology criteria for adverse events, EGFR= estimated glomerular filtration rate, EMR= electronic medical record, EORTC QLQ-MY20= European Organization for Research and Treatment
of Cancer Quality of Life Group Myeloma questionnaire, QLQ-C30= European Organization for Research and Treatment of Cancer Quality of Life Group Core questionnaire, HRQoL = Health-related Quality of Life.
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with both including HRQoL (functioning and symptoms), pain,
fatigue, body image and sexual problems. In the Spanish set,
outcomes on treatment adherence and preferences and satisfaction
were included, which were not defined in our set. On the contrary,
we included neuropathy, relationship/marital problems and
symptoms frequently reported by patients with MM (such as
specific areas of the bodywith pain, aches andworries about health
and future as measured by the EORTC QLQ MY-2025) and a
single itemon fear of physical exercise thatwere not included in the
Spanish set. The overlap in these two outcome sets suggests that
outcomes that matter most to patients with MM are similar for
patients living in a Northern European or Southern European
country. In the future, efforts to harmonize both the Spanish and
the Dutch outcome set to an international standardized set will be
made to compare results in Europe or even worldwide, in which
cultural differences will be considered.
As a next step we are implementing the outcome set in 5 pilot
hospitals in the Netherlands which will be coordinated by a
steering committee. Barriers such as time, logistics and
unfamiliarity with PROs will challenge use in daily clinical
practice in a first introduction period. With respect to the clinical
outcomes, the majority is registered in routine clinical practice,
although not in a standardized manner. Standardized sets in the
electronic medical record may help facilitate structured recording
of outcomes such as infections and neuropathy via the CTCAE
criteria in a standardized manner. The accuracy and complete-
ness of data, as well as the response of patients to PROMs, is
crucial for the relevance of the data and will be evaluated after the
implementation in the pilot hospitals. Since data will be collected
of every individual patient this will result in population-based
information on outcomes, which is of merit compared to
outcomes collected in selected trial populations. By understand-
ing that the outcomes of the questionnaires will be discussed
during clinical visits and if needed treatment adjustments will be
made, patients will feel more involved in their care and are
hopefully more likely to complete PROMs.
The strength of this study is reflected by the joint effort of a
large group of panelists with diverse expertise from four
hospitals. However, there were several limitations to the
development of the standardized outcome set. The defined
outcome set has been derived from consensus opinions of the
panel, based on the currently available scientific evidence and
experience, and not been developed using a structured method
(for example a Delphi method). As the implementation phase of
the set of outcomes for use in daily clinical practice is ongoing,
results about the feasibility of outcomemeasurement using the set
will follow in the near future. There will be an annual update in
the HOVON MM working group to evaluate and discuss its
relevance for patients and health care professionals.
In conclusion, we have set out to produce relevant outcomes
that matter most to patients with MM and implementation is
currently ongoing in 5 pilot hospitals. Future goal is to enroll an
outcome set in all hospitals in the Netherlands and abroad, in
order to carry out continuous and measurable improvement of
outcomes for patients with MM.
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Appendix A: Overview of potential outcomes
for patients with MM.
Potential clinical outcomes
Neuropathy
Polyneuropathy
Fracture
Paraplegia
Vertebral collapse
Pulmonary embolism
Diabetes
Cardiomyopathy
Kidney failure
Psychogenic side effects
Anemia
Platelets deficiency
Thrombosis
Swollen face
Infections
Increased body weight
Fever
Place of death
Palliative care
Hospital admission prior to death
Treatments prior to death
Potential patient-reported outcomes
Pain
Fatigue
Sleep disorder
Stamina
Difficulty sleeping
Muscle weakness
Backache
Posture change
Movement problems
ADL
iADL
Mobility problems
Disability
Shortness of breath
Baldness
Skin problems
Problems with joints
Swallowing problems
Problems with taste
Nausea
Abdominal problems
Problems concentrating (focus)
Anxiety
Fear
Depression
Disappointment
Autonomy problems
Coping
Fear of physical exercise
Problems setting boundaries
Future perspective
Cosmetic self-image
Mental self-image
Social activities
Recreation and leisure
Ability to work
Relationships
Sexual problems
Financial problems
Anger (especially if in quarantine)
Loneliness (especially if in quarantine)
Letter Patient Centered Outcome Set for Patients With Multiple Myeloma
6
